An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 in Subjects With Familial Hypercholesterolemia May 5, 2022 By Jesse Bufkin
Hematopoietic Bone Marrow Transplantation for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Co May 5, 2022 By Jesse Bufkin
Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen May 5, 2022 By Jesse Bufkin
The Effect of allogeneic Hematopoietic Cell Transplantation on the Activity and Progression of Multiple Sclerosis May 5, 2022 By Jesse Bufkin
A Phase I Trial Evaluating Escalating Doses of 131I-BC8 (Anti-CD45) followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies May 5, 2022 By Jesse Bufkin
A PhaseI/II Study of High-Dose Immunosuppressive Therapy (HDIT) Using Carustine, Etoposide, Cytarabine and Melphalan (BEAM) + Thymoglobulin, and Autologous CD34+Hematopoietic Stem Cell Transplant (HCT) for the Treatment of Poor Prognosis Multiple Sclerosi May 5, 2022 By Jesse Bufkin
A pilot study to evaluate the safety and feasibility of cellular immunotherapy using genetically modified autologous CD20-specific T cells for patients with relapsed or refractory mantle cell and indolent B cell lymphomas-2154 May 5, 2022 By Jesse Bufkin
Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen May 5, 2022 By Jesse Bufkin
Bortezomib and Vorinostat as Maintenance Therapy after Autologous Stem Cell Transplant for Multiple Myeloma May 5, 2022 By Jesse Bufkin
Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen May 5, 2022 By Jesse Bufkin
